Opinion
Video
Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations
Explore the prevalence of hemophilia A in the United States and its profound clinical impact on patients, delving into the challenges and implications of managing this bleeding disorder. Additionally, gain valuable insights into the economic costs associated with the comprehensive care required for individuals with hemophilia A, shedding light on the financial burdens faced by both patients and healthcare systems.
This is a video synopsis/summary of an Insights involving Allison Wheeler, MD.
In the United States, hemophilia A occurs in about 1 in 5000 live male births, with about 400 babies born with it each year. Estimates suggest there are about 33,000 male patients living with the disorder, though some mild cases in males and females may be undiagnosed.
The clinical impact varies based on disease severity, categorized by clotting factor VIII levels: less than 1% is severe, 1% to 5% is moderate, and 6% to 50% is mild. Those with severe disease have spontaneous bleeding and bleeding with minor trauma, significantly impacting quality of life. Moderate disease (1%-5% factor VIII) has variable impacts. Those with mild disease (6%-50%) mostly bleed with major trauma or surgery.
Economic costs also vary by severity. Adults with severe disease are recommended prophylactic therapy to prevent bleeds, costing $500,000 to $750,000 yearly. Additional factor VIII is needed to manage breakthrough bleeds. Hospitalizations for bleeding or surgery mean lost work/school days. Patients who can self-infuse factor VIII at home may avoid hospitalization for minor bleeds. Those with moderate/mild disease self-infuse less often, so they need hospitalization more often when bleeding occurs. In summary, hemophilia A has variable but often greatly impactful clinical and economic consequences.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
